- Home
- BRIA vs TLSA Comparison
BRIA vs TLSA Comparison
Compare BRIA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- TLSA
- Stock Information
- Founded
- BRIA 2011
- TLSA 2013
- Country
- BRIA Singapore
- TLSA United Kingdom
- Employees
- BRIA N/A
- TLSA N/A
- Industry
- BRIA
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- TLSA Health Care
- Exchange
- BRIA NYSE
- TLSA Nasdaq
- Market Cap
- BRIA 73.0M
- TLSA 87.8M
- IPO Year
- BRIA 2024
- TLSA 2000
- Fundamental
- Price
- BRIA $2.65
- TLSA $1.37
- Analyst Decision
- BRIA
- TLSA
- Analyst Count
- BRIA 0
- TLSA 0
- Target Price
- BRIA N/A
- TLSA N/A
- AVG Volume (30 Days)
- BRIA 19.0K
- TLSA 1.3M
- Earning Date
- BRIA 03-18-2025
- TLSA 03-18-2025
- Dividend Yield
- BRIA N/A
- TLSA N/A
- EPS Growth
- BRIA N/A
- TLSA N/A
- EPS
- BRIA 92.24
- TLSA N/A
- Revenue
- BRIA $55,755,669.00
- TLSA N/A
- Revenue This Year
- BRIA N/A
- TLSA N/A
- Revenue Next Year
- BRIA N/A
- TLSA N/A
- P/E Ratio
- BRIA $0.03
- TLSA N/A
- Revenue Growth
- BRIA 8.03
- TLSA N/A
- 52 Week Low
- BRIA $2.30
- TLSA $0.41
- 52 Week High
- BRIA $4.38
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- TLSA 61.50
- Support Level
- BRIA N/A
- TLSA $0.92
- Resistance Level
- BRIA N/A
- TLSA $1.91
- Average True Range (ATR)
- BRIA 0.00
- TLSA 0.23
- MACD
- BRIA 0.00
- TLSA 0.05
- Stochastic Oscillator
- BRIA 0.00
- TLSA 51.35
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.